TP53 and head and neck squamous cell carcinoma: Moreover, this leads to increased sensitivity to ionizing radiation (IR is a staple of SCCHN therapy) when combined with inhibition of glycolysis in TP53 mutant cells, but not in TP53 wild-type cells.